115 related articles for article (PubMed ID: 10956186)
1. A refined 3-dimensional QSAR of cytochrome P450 2C9: computational predictions of drug interactions.
Rao S; Aoyama R; Schrag M; Trager WF; Rettie A; Jones JP
J Med Chem; 2000 Jul; 43(15):2789-96. PubMed ID: 10956186
[TBL] [Abstract][Full Text] [Related]
2. Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors.
Ekins S; Bravi G; Binkley S; Gillespie JS; Ring BJ; Wikel JH; Wrighton SA
Drug Metab Dispos; 2000 Aug; 28(8):994-1002. PubMed ID: 10901712
[TBL] [Abstract][Full Text] [Related]
3. Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9.
Mancy A; Dijols S; Poli S; Guengerich P; Mansuy D
Biochemistry; 1996 Dec; 35(50):16205-12. PubMed ID: 8973193
[TBL] [Abstract][Full Text] [Related]
4. The substrate binding site of human liver cytochrome P450 2C9: an NMR study.
Poli-Scaife S; Attias R; Dansette PM; Mansuy D
Biochemistry; 1997 Oct; 36(42):12672-82. PubMed ID: 9335524
[TBL] [Abstract][Full Text] [Related]
5. Competitive CYP2C9 inhibitors: enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis.
Afzelius L; Zamora I; Ridderström M; Andersson TB; Karlén A; Masimirembwa CM
Mol Pharmacol; 2001 Apr; 59(4):909-19. PubMed ID: 11259637
[TBL] [Abstract][Full Text] [Related]
6. Enzymatic determinants of the substrate specificity of CYP2C9: role of B'-C loop residues in providing the pi-stacking anchor site for warfarin binding.
Haining RL; Jones JP; Henne KR; Fisher MB; Koop DR; Trager WF; Rettie AE
Biochemistry; 1999 Mar; 38(11):3285-92. PubMed ID: 10079071
[TBL] [Abstract][Full Text] [Related]
7. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9.
He M; Korzekwa KR; Jones JP; Rettie AE; Trager WF
Arch Biochem Biophys; 1999 Dec; 372(1):16-28. PubMed ID: 10562412
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily.
Ha-Duong NT; Dijols S; Marques-Soares C; Minoletti C; Dansette PM; Mansuy D
J Med Chem; 2001 Oct; 44(22):3622-31. PubMed ID: 11606127
[TBL] [Abstract][Full Text] [Related]
9. Identification of amino acid substitutions that confer a high affinity for sulfaphenazole binding and a high catalytic efficiency for warfarin metabolism to P450 2C19.
Jung F; Griffin KJ; Song W; Richardson TH; Yang M; Johnson EF
Biochemistry; 1998 Nov; 37(46):16270-9. PubMed ID: 9819219
[TBL] [Abstract][Full Text] [Related]
10. Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase).
Jones BC; Hawksworth G; Horne VA; Newlands A; Morsman J; Tute MS; Smith DA
Drug Metab Dispos; 1996 Feb; 24(2):260-6. PubMed ID: 8742240
[TBL] [Abstract][Full Text] [Related]
11. Development of a combined protein and pharmacophore model for cytochrome P450 2C9.
de Groot MJ; Alex AA; Jones BC
J Med Chem; 2002 May; 45(10):1983-93. PubMed ID: 11985466
[TBL] [Abstract][Full Text] [Related]
12. The substrate binding site of human liver cytochrome P450 2C9: an approach using designed tienilic acid derivatives and molecular modeling.
Mancy A; Broto P; Dijols S; Dansette PM; Mansuy D
Biochemistry; 1995 Aug; 34(33):10365-75. PubMed ID: 7654690
[TBL] [Abstract][Full Text] [Related]
13. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes.
Yamazaki H; Inoue K; Chiba K; Ozawa N; Kawai T; Suzuki Y; Goldstein JA; Guengerich FP; Shimada T
Biochem Pharmacol; 1998 Jul; 56(2):243-51. PubMed ID: 9698079
[TBL] [Abstract][Full Text] [Related]
14. Sulfaphenazole derivatives as tools for comparing cytochrome P450 2C5 and human cytochromes P450 2Cs: identification of a new high affinity substrate common to those enzymes.
Marques-Soares C; Dijols S; Macherey AC; Wester MR; Johnson EF; Dansette PM; Mansuy D
Biochemistry; 2003 Jun; 42(21):6363-9. PubMed ID: 12767217
[TBL] [Abstract][Full Text] [Related]
15. Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism.
Miners JO; Rees DL; Valente L; Veronese ME; Birkett DJ
J Pharmacol Exp Ther; 1995 Mar; 272(3):1076-81. PubMed ID: 7891318
[TBL] [Abstract][Full Text] [Related]
16. Studies of flurbiprofen 4'-hydroxylation. Additional evidence suggesting the sole involvement of cytochrome P450 2C9.
Tracy TS; Marra C; Wrighton SA; Gonzalez FJ; Korzekwa KR
Biochem Pharmacol; 1996 Oct; 52(8):1305-9. PubMed ID: 8937439
[TBL] [Abstract][Full Text] [Related]
17. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
[TBL] [Abstract][Full Text] [Related]
18. Arginines 97 and 108 in CYP2C9 are important determinants of the catalytic function.
Ridderström M; Masimirembwa C; Trump-Kallmeyer S; Ahlefelt M; Otter C; Andersson TB
Biochem Biophys Res Commun; 2000 Apr; 270(3):983-7. PubMed ID: 10772937
[TBL] [Abstract][Full Text] [Related]
19. Site-directed mutagenesis of mouse steroid 7 alpha-hydroxylase (cytochrome P-450(7) alpha): role of residue-209 in determining steroid-cytochrome P-450 interaction.
Iwasaki M; Lindberg RL; Juvonen RO; Negishi M
Biochem J; 1993 Apr; 291 ( Pt 2)(Pt 2):569-73. PubMed ID: 8484736
[TBL] [Abstract][Full Text] [Related]
20. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor.
Tang C; Shou M; Mei Q; Rushmore TH; Rodrigues AD
J Pharmacol Exp Ther; 2000 May; 293(2):453-9. PubMed ID: 10773015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
